IGFBP2 and non-small cell lung carcinoma: Furthermore, intrinsic resistance to dasatinib in a panel of non-small-cell lung cancer cell lines has been causally linked to the upregulation of Insulin-like growth factor (IGF)-binding protein-2 (IGFBP2) which acts as a carrier protein for the IGF ligands [67].